

AWARD NUMBER: W81XWH-15-1-0420

TITLE: Cellular Energy Pathways as Novel Targets for the Therapy of Autosomal Dominant Polycystic Kidney Disease

PRINCIPAL INVESTIGATOR: Kenneth R. Hallows, MD, PhD, FASN

CONTRACTING ORGANIZATION: University of Southern California  
Dept. of Contracts & Grants  
3720 S. Flower St., 3<sup>rd</sup> Fl.  
Los Angeles, CA 90089-0701

REPORT DATE: September 29, 2017

TYPE OF REPORT: Annual Progress Report

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

# REPORT DOCUMENTATION PAGE

*Form Approved*  
*OMB No. 0704-0188*

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

<b>1. REPORT DATE</b> 29-09-2017		<b>2. REPORT TYPE</b> Annual		<b>3. DATES COVERED</b> 1 Sep 2016 - 31 Aug 2017	
<b>4. TITLE AND SUBTITLE</b>  Cellular Energy Pathways as Novel Targets for the Therapy of Autosomal Dominant Polycystic Kidney Disease				<b>5a. CONTRACT NUMBER</b> W81XWH-15-1-0420	
				<b>5b. GRANT NUMBER</b> PR140468P1	
				<b>5c. PROGRAM ELEMENT NUMBER</b>	
<b>6. AUTHOR(S)</b> Kenneth R. Hallows, MD, PhD Michael J. Caplan, PhD, MD  E-Mail: hallows@usc.edu				<b>5d. PROJECT NUMBER</b>	
				<b>5e. TASK NUMBER</b>	
				<b>5f. WORK UNIT NUMBER</b>	
<b>7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)</b> University of Southern California Los Angeles, CA 90089-0701  Yale University New Haven, CT 06520				<b>8. PERFORMING ORGANIZATION REPORT NUMBER</b>	
<b>9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)</b>  U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				<b>10. SPONSOR/MONITOR'S ACRONYM(S)</b>	
				<b>11. SPONSOR/MONITOR'S REPORT NUMBER(S)</b>	
<b>12. DISTRIBUTION / AVAILABILITY STATEMENT</b>  Approved for Public Release; Distribution Unlimited					
<b>13. SUPPLEMENTARY NOTES</b>					
<b>14. ABSTRACT</b> Autosomal dominant polycystic kidney disease (ADPKD) is a common inherited disorder where patients, over the course of decades, develop large fluid filled cysts that damage the normal kidney tissue and can lead ultimately to kidney failure that necessitates transplantation or dialysis. There are currently no FDA-approved medications for this condition. Recent research reveals that the formation of cysts is due in part both to inappropriate cell growth, fluid secretion, and dysregulation of cellular energy metabolism. The enzyme AMPK regulates a number of cellular pathways, including these disease-causing features. Drugs that activate AMPK, therefore, may constitute an effective therapeutic option for slowing or preventing cyst growth in ADPKD. This research project is aimed at examining the potential of approved, widely used, inexpensive and low-toxicity drugs that can activate AMPK (metformin, simvastatin, and salicylates) and or promote oxidative metabolism (dichloroacetic acid) as potential therapies for the treatment of ADPKD. During this past research period, we measured and analyzed various metabolomic biomarkers in samples derived from cell lysates and urine and continued collecting cyst growth data in ADPKD <i>in vitro</i> cell culture models and urine specimens derived from a broad cross-section of patients with ADPKD. We also began collecting <i>in vivo</i> data by performing dose-ranging studies of metformin and salicylates in mice.					
<b>15. SUBJECT TERMS</b> Autosomal Dominant Polycystic Kidney Disease, Polycystins, Metformin, Statins, Salicylates, Dichloroacetic acid, AMP-activated Protein Kinase, Biomarkers, Metabolism, Mass Spectrometry					
<b>16. SECURITY CLASSIFICATION OF:</b>			<b>17. LIMITATION OF ABSTRACT</b>  Unclassified	<b>18. NUMBER OF PAGES</b>  24	<b>19a. NAME OF RESPONSIBLE PERSON</b> USAMRMC
<b>a. REPORT</b>  Unclassified	<b>b. ABSTRACT</b>  Unclassified	<b>c. THIS PAGE</b>  Unclassified			<b>19b. TELEPHONE NUMBER</b> (include area code)

## Table of Contents

	<u>Page</u>
1. Introduction.....	4
2. Keywords.....	5
3. Accomplishments.....	6
4. Impact.....	18
5. Changes/Problems.....	19
6. Products.....	20
7. Participants & Other Collaborating Organizations.....	21
8. Special Reporting Requirements.....	24
9. Appendices.....	N/A